Purpose This study aimed to investigate the relationship between loss of AT-rich interactive domain-containing protein 1A (ARID1A) expression and the prognosis of patients with oral squamous cell carcinoma (OSCC). Methods Seventy-five OSCC tissue specimens were immunohistochemically stained with a specific antibody to ARID1A. The immunoreactivity of ARID1A was then correlated with clinicopathological factors, including the prognosis of the patients. Results Non-tumorous oral squamous cells exhibited nuclear ARID1A staining, whereas the invasive OSCC cells showed different degrees of loss of ARID1A immunoreactivity. Little-to-no ARID1A immunoreactivity was found at the cancer inva - sion front in 20 of the 75 OSCC tissue specimens, with significant association with unfavorable patient outcomes. Notably, downregulation of ARID1A immunoreactivity was also related to lymphovascular involvement and poor outcome in patients with T1 and T2 OSCC without lymph node metastasis. Conclusions The results suggest that loss of ARID1A expression at the cancer invasion front might be related to tumor progression in many OSCCs. Keywords Oral squamous cell carcinoma · ARID1A · Chromatin remodeling complex · Outcome Introduction therapies, it is important to unravel the molecular pathways of OSCC progression. The incidence of oral squamous cell carcinoma (OSCC) AT-rich interactive domain-containing protein 1A has increased in recent years , and
Oral Cancer – Springer Journals
Published: Jan 19, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera